Articles related to PANCREATIC CANCER

The FDA’s approval of irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin marks a pivotal advancement in first-line treatment options for metastatic pancreatic adenocarcinoma, showcasing a notable increase in overall and progression-free survival rates.

Explore groundbreaking therapies in the pipeline: Onivyde for pancreatic cancer, showing marked survival benefits, and roluperidone, offering new hope in managing schizophrenia’s negative symptoms.

Explore innovative options for patients with pancreas, liver and biliary cancers at the Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2023.

Take part in an engaging multidisciplinary discussion on the evolving dynamics of hepato-pancreatico-biliary cancers. Discover, learn, and prepare to integrate these new strategies into your clinical practice.

Neoadjuvant Chemotherapy and Upfront Surgery: A Comparative Study in Resectable Pancreatic Cancer In a recent study presented at the 2023 ASCO Annual Meeting, researchers found no significant survival benefit of neoadjuvant chemotherapy over upfront surgery in patients with resectable pancreatic cancer. Key Points: “Results of this trial do not support neoadjuvant FOLFIRINOX as standard of care in resectable pancreatic cancer.” Knut Jørgen Labori, MD, PhD, Oslo University Hospital, Norway

Unraveling gene-specific cancer risks in first-degree relatives of PDAC probands sheds light on a higher uptake of genetic cascade testing. Recent data suggests that first-degree relatives of patients with pancreatic ductal adenocarcinoma (PDAC) who carry pathogenic germline variants (PGVs) in specific cancer syndrome-associated genes face heightened cancer risks. The study focuses on PDAC probands carrying PGVs in nine such genes: ATM, BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6, PMS2, and CDKN2A. To date, these risks hadn’t been comprehensively analyzed. The study analyzed 234 PDAC probands with PGVs, selected from a pool of 4,562 participants who underwent genetic testing. Findings suggest that different genes correlate to distinct types of cancer. For instance, female relatives of probands with BRCA1 and BRCA2 variants showed significantly increased risks of ovarian and breast cancer. First-degree relatives of probands with Lynch syndrome mismatch repair variants exhibited higher risks of uterine, endometrial, and colon cancer. Additionally, the risk of PDAC itself rose with variants in ATM, BRCA2, CDKN2A, and PALB2, with melanoma risk escalating for relatives of probands with CDKN2A variants. Overall, this research underscores that gene-specific PDAC and extra-PDAC cancer risks in first-degree relatives of PDAC probands are linked with the presence of PGVs in nine cancer […]